Back to Search
GREGORY PLAUTZ, MD
MD
Pediatric Hematology & Oncology Physician
NPI: 1447215132Individual
Specialties, Licenses & Credentials
Pediatric Hematology & Oncology PhysicianPrimary
Pediatrics — Pediatric Hematology-Oncology
Code: 2080P0207X
35067893(OH)
Research & Publications (19)
Considerations on clinical use of T cell immunotherapy for cancer.
PMID 12956434·Arch Immunol Ther Exp (Warsz)·2003
6-review
Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors.
PMID 11034369·J Immunol·2000
7-preclinical
Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response.
PMID 17284532·Blood·2007
7-preclinical
Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination.
PMID 17207783·Cell Immunol·2006
7-preclinical
Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells.
PMID 16230420·Cancer Res·2005
7-preclinical
Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines.
PMID 16121986·J Neurosurg·2005
7-preclinical
Adoptive immunotherapy of cancer with polyclonal, 108-fold hyperexpanded, CD4+ and CD8+ T cells.
PMID 15566571·J Transl Med·2004
8-other
Memory T cells originate from adoptively transferred effectors and reconstituting host cells after sequential lymphodepletion and adoptive immunotherapy.
PMID 15004146·J Immunol·2004
7-preclinical
Tumor-induced L-selectinhigh suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy.
PMID 12391191·J Immunol·2002
7-preclinical
Adoptive immunotherapy of advanced tumors with CD62 L-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion.
PMID 12218152·J Immunol·2002
7-preclinical
Adoptive immunotherapy of CNS malignancies.
PMID 11686021·Cancer Chemother Biol Response Modif·2001
6-review
T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance.
PMID 11642606·Crit Rev Immunol·2001
6-review
Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation.
PMID 11283503·Otolaryngol Head Neck Surg·2001
7-preclinical
T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-gamma mechanisms that cannot be predicted from in vitro T cell characteristics.
PMID 11120842·J Immunol·2000
7-preclinical
Helper-independent, L-selectinlow CD8+ T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression.
PMID 11067932·J Immunol·2000
7-preclinical
Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study.
PMID 11031409·Arch Otolaryngol Head Neck Surg·2000
5-case
CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection.
PMID 10770269·Crit Rev Immunol·2000
6-review
Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas.
PMID 10728667·Cancer Res·2000
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 9500 EUCLID AVE
CLEVELAND, OH 44195 - Phone
- (800) 223-2273
Quick Facts
- NPI
- 1447215132
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 19
Are you this provider?
Claim Your Profile